Search Main Menu Main Content

Choose language
Change contrast :
Standards Reinforced

icone

HAS profile

Mission
Organisational Structure
Ethics, transparency and management of conflicts of interest

International relations and projects
Publications

Recherche

icone plus
My account

Email alert Subscription

Newsletter Subscription

My search

Refresh

Please fill in your email address to retrieve your email alerts subscriptions.

New subscription

Please fill in your email address to retrieve your newsletter subscriptions.

You do not have a saved search
No element in selection
Contact

1 result

Type : Practice guidelines
Topics : Pulmonary and pleural diseases
Active substance : lopinavir
Active substance : norfloxacine
Active substance : rifampicine

Topic

Diseases and conditions (1)
Plus ...
- Respiratory tract diseases (1)
- Plus ...
  - Pulmonary and pleural diseases (1)
  - Bronchial diseases (1)
Population groups (1)
Plus ...
- Paediatrics (1)

Practice Guidelines and Other Guides (1)
Plus ...
- Practice guidelines (1)

industriels (1)

Français (1)

Active substance

alcool (1)
allopurinol (1)
aminophylline (1)
aspirine (1)
carbachol (1)
ciprofloxacine (1)
clarithromycine (1)
fluconazole (1)
flunisolide (1)
halothane (1)
iode (1)
itraconazole (1)
josamycine (1)
lopinavir (1)
mannitol (1)
norfloxacine (1)
pentoxifylline (1)
prednisolone (1)
prednisone (1)
primidone (1)
propionate de fluticasone (1)
rifabutine (1)
rifampicine (1)
ritonavir (1)
roxithromycine (1)
salbutamol (1)
stiripentol (1)

Première page
Page précédente
/ 1
Page suivante
Dernière page

Sorted by :Title

Relevance
Date

Medical follow-up of patients with asthma - Adults and adolescents

Practice guidelines - Posted on 01/09/2004

Download abstract

Add to my selection

Première page
Page précédente
/ 1
Page suivante
Dernière page
10 par pages

Advancing quality in the fields of health and social care services

Follow us :

Eunetha.eu
Pasq.eu

All our publications by topic and type

Opinions on medicines
Opinions on medical devices
INAHTA briefs

Français
English

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

UHBjvsgm6JFSDGJ0